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Multiple myeloma (MM) bone disease is characterized by osteolytic bone tissue destruction resulting in bone pain, fractures,
vertebral collapse, and spinal cord compression in patients. Upon initial diagnosis ofMM, almost 80% of patients suffer from bone
disease. Earlier diagnosis and intervention in MM bone disease would potentially improve treatment outcome and patient
survival. New preclinical models are needed for developing novel diagnostic markers of bone structural changes as early as
possible in the disease course. Here, we report a proof-of-concept, syngeneic, intrafemoral MOPC315.BM MMmurine model in
skeletally mature BALB/c mice for detection and characterization of very early changes in the extracellular matrix (ECM) of MM-
injected animals. Bioluminescence imaging (BLI) in vivo confirmed myeloma engraftment in 100% of the animals with high
osteoclast activity within 21 days after tumor cell inoculation. Early signs of aggressive bone turnover were observed on the outer
bone surfaces by high-resolution microcomputed tomography (microCT). Synchrotron phase contrast-enhanced microcomputer
tomography (PCE-CT) revealed very local microarchitecture differences highlighting numerous active sites of erosion and new
bone at the micrometer scale. Correlative backscattered electron imaging (BSE) and confocal laser scanning microscopy allowed
direct comparison of mineralized and nonmineralized matrix changes in the cortical bone. 0e osteocyte lacunar-canalicular
network (OLCN) architecture was disorganized, and irregular-shaped osteocyte lacunae were observed in MM-injected bones
after 21 days. Our model provides a potential platform to further evaluate pathological MM bone lesion development at the micro-
and ultrastructural levels. 0ese promising results make it possible to combine material science and pharmacological investi-
gations that may improve early detection and treatment of MM bone disease.
1. Introduction
Among the patients diagnosed with multiple myeloma
(MM), 80% already suffer fromMM bone disease, exhibiting
osteolytic bone tissue destruction or osteopenia, with
symptoms of severe pain and fractures [1]. Morbidity and
mortality due to MM bone disease are high, and quality of
life is severely affected by skeletal-related pathologies [1, 2].
MM is rarely curable and is the second most common
hematological neoplasia in the USA and Europe with an age-
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adjusted incidence of six per 100,000 people/year and a
median age of 69 [3].0e pathological cells are clonal plasma
cells in the bone marrow that secrete excessive amounts of
monoclonal immunoglobulins. MM cells diffusely infiltrate
the bone marrow or grow as multiple focal lesions. In ad-
vanced stages, extramedullary lesions develop. MM cells
inhibit osteoblast differentiation and stimulate osteoclast
function [4] resulting in increased bone resorption and
characteristic osteolytic punched-out bone lesions as well as
osteopenia. 0e current gold standard of treatment includes
the use of bisphosphonates, local irradiation, and orthopedic
intervention [1]. To date, MM treatment has not succeeded
in healing bone lesions or regenerating bone tissue even in
the absence of signs of active disease [5]. New approaches are
urgently needed to lead to better detection and improved
monitoring of bone structural changes as early as possible in
the disease course, ideally before overt lytic lesions develop.
0is is critical for future improvements in diagnosis, novel
treatment development, and for raising quality of life in MM
patients, typically elderly patients.
Preclinical animal models are essential for the above
and for developing novel diagnostic markers. 0ey are also
essential to better understand interactions between the
extracellular matrix and tumor cells. Especially for human
MM bone disease, reliable mouse models facilitate tracking
lesion formation, expansion, and localization in the very
early stages of the disease because they further help
benchmark and quantify disease severity. We previously
established the murine MOPC315.BM MM model [6].
Extensive osteolytic bone disease was demonstrated be-
tween 5 and 8 weeks after intravenous tumor cell injection
in young 6-week-old BALB/c mice. Mice repetitively
succumbed to paraplegia and extramedullary growth of
MOPC315.BM.Luc cells [6].
Since MM is prevalent in aging populations, it is im-
portant to examine skeletally mature (adult) bones that
differ substantially from young developing bones, where
the mineralized tissue naturally undergoes extensive (re)
modelling [7, 8]. Bone turnover, bone architecture, and
adaptive bone formation/resorption substantially differ in
bones of adult mice as compared with bones of young mice
[9]. Higher bone formation and resorption activities in
young (6 weeks old) compared to mature (16 weeks old)
mice were linked to higher frequencies of growing
osteolytic skeletal metastasis in in vivo models of breast and
prostate cancer [10]. 0is however is very different in aging
populations mostly suffering from MM disease, where
normal bone turnover is very low.0ere is thus a great need
for novel, syngeneic skeletally mature models of MM bone
disease.
Here, we describe an intrafemoral (i.f.) murine MM
model, where the disease is engrafted using
MOPC315.BM.Luc cells [6, 11, 12]. 0is syngeneic model
was created (i) to establish a controlled MMmodel in adult
mice, (ii) to track disease development over time, and (iii)
to confine MM disease primarily to one particular bone
site. We further used the model (iv) to correlate MM
engraftment by in vivo bioluminescence imaging (BLI) and
(v) to facilitate high-resolution 3D mapping using a
multiscale, multimodal material characterization
approach.
2. Materials and Methods
2.1. Intrafemoral Injections and Bioluminescence Imaging
(BLI). 26-week-old female BALB/c mice were obtained from
Charles River (Sulzfeld, Germany). Local authorities approved
all animal experiments (55.2 DMS-2532-2-31, Regierung of
Unterfranken, Wu¨rzburg, Germany). 0e study was carried out
in accordance with the replacement, reduction, refinement (3Rs)
principle. BALB/c mice were either injected with PBS (n=1) or
with 105 luciferase-positive MOPC315.BM.Luc cells (n=10) [6],
directly into the right femora between the condyles, through the
patellar surface, into the bone marrow cavity. Mice were sac-
rificed on day 7 (n=2), day 11 (n=2), day 15 (n=3), and day 21
(n=3) after injection. BLI was performed in vivo to confirm
MOPC315.BM.Luc cell engraftment and to monitor tumor
progression over time as described previously [6]. Mice were
sacrificed through cervical dislocation. 0e PBS control mouse
was sacrificed at day 21.0e severity ofMMbone disease activity
was quantified using Living Image 4.4 (PerkinElmer, Massa-
chusetts, USA), and graphs were created with Prism 7 software
(GraphPad, San Diego, USA). Femora were dissected, fixed in
4% paraformaldehyde for 48 hours, and transferred to 70%
ethanol.
2.2. Tartrate-Resistant Acid Phosphatase (TRAP) Staining.
For tartrate-resistant acid phosphatase (TRAP) staining,
samples were dehydrated in increasing concentrations of
ethanol, stained with 0.02 wt.% rhodamine 6G (AppliChem,
St. Louis, USA), and prepared for cold embedding in
polymethylmethacrylate (PMMA) (Technovit 9100, Heraeus
Kulzer, Wehrheim, Germany). Nuclei counterstaining was
achieved using Mayer’s haematoxylin (MHS32, Sigma,
Germany) applied for 20 seconds, washed in water, and
blued in 0.1% ammonium hydroxide. A digital light mi-
croscope (VHX-S550E, Keyence, Neu-Isenburg, Germany)
was used to image the stained sections.
2.3. Microcomputed Tomography (MicroCT) Imaging. For
microcomputed tomography (microCT) imaging, samples
were maintained in an ethanol atmosphere. Each bone was
mounted in a 2ml polyvinyl alcohol (PVA) vial (Sarstedt,
Nu¨mbrecht, Germany), centrally stabilized in styropore, and
padded with a polyester foam saturated with 70% ethanol.
MOPC315.BM.Luc samples were scanned using a Skyscan
1172 (Bruker microCT, Kontich, Belgium) with 2 μm and
13.2 μm effective pixel sizes, X-ray source set to 70 kV with a
1mm thick aluminum filter, 2 s exposure time, and 1800
projections. Data were reconstructed (NRecon, Bruker
microCT, Kontich, Belgium) and examined in 2D (ImageJ
1.52d, National Institutes of Health, Maryland, USA) and 3D
(CTvox, Bruker microCT, Kontich, Belgium) to identify re-
gions of high turnover and osteolytic lesions.
PMMA-embedded femora were scanned using an
EasyTom 160 (RX Solutions, Chavanod, France). Scanning
parameters were 45 kV, 45 μA, 2.5 μm voxel size, one frame
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per second, average frame of 8, and 1120 projections. Re-
construction of scan projections was performed using RX
Solutions X-Act software.
2.4. Synchrotron Phase Contrast-Enhanced (PCE) MicroCT
Imaging. Regions above the condyles extending ∼1.5mm in
length and covering the whole bone diameter were scanned on
ID19 of the European Synchrotron Radiation Facility (ESRF,
Grenoble, France). Synchrotron PCE-CT scans were recorded
using the 34 keV harmonic in pink-beam mode and 650nm
effective pixel size, employing 45mm propagation distance
between the sample and detector (LSO scintillators and PCO
edge camera). Typical scans required ∼5000 radiographic
projections, with 300ms exposure time, continuously rotating
the samples by 360° using the so-called half acquisition mode.
ESRF in-house code was used to reconstruct the data, en-
hancing contrast by means of Paganin-based filtering with a
delta/beta ratio of 500 [13].
2.5. Backscattered Electron Imaging (BSE). Backscattered
electron (BSE) imaging was performed to investigate bone
morphology andmineral content (brighter grey corresponds
to higher mineral content) on regions with cortical lesions.
Regions of interest were identified using high-resolution
microCT. Controlled angle serial sectioning was performed
to expose the PMMA block surface. BSE images were ob-
tained using an environmental scanning electron micro-
scope (FEI FEG-ESEM Quanta 600, FEI Company,
Hillsboro, USA). 0is microscope operates at low vacuum
(0.75 Torr), an accelerating voltage of 12.5 kV, a working
distance of 9.9mm, and a spot size of 4.0 [14]. Images taken
at 100x magnification were merged together. Imaging
conditions followed established quantitative backscattered
electron imaging protocols for measurement of the mineral
density distribution in human bone biopsies [15].
2.6. Fluorescence Confocal Laser Scanning Microscopy
(CLSM). Correlative imaging of the osteocyte lacunar-can-
alicular network (OLCN)was performed on the same exposed
PMMA surface using a fluorescence confocal laser scanning
microscope (CLSM, Leica TCS SP8 DLS Multiphoton,
Wetzlar, Germany) [16]. 0e OLCN was visualized using
λexcitation = 514 nm/λemission = 550-650 nm laser light, magni-
fication 40x, oil objective, 0.75 zoom, 6 tiles, 60 μm total depth
at 0.4 μm step size. Multiple images were then merged.
For the network characterization, we used an established
protocol based on previously published work [17, 18]. In short,
raw CLSM data were segmented to automatically differentiate
between canaliculi and lacunae based on their bulkiness. All
datasets were then evaluated with the same segmentation
parameter set. 0e average lacunae volume was calculated by
counting segmented lacuna voxels and dividing by the total
number of lacunae. 0e segmented canaliculi were then
skeletonized and rendered into a 3D network for further
quantitative analysis. Using this network, we then computed
the canalicular density which quantifies the total length of
















































Figure 1: Detection of MOPC315.BM.Luc cells in 26-week-old BALB/c mice following inoculation. (a) BLI images of ventral and lateral
views of a MOPC315.BM.Luc- and a PBS-injected mouse at increasing days after inoculation. (b) BLI signals (total flux in photons−1) of one
control and ten MM mice at days after inoculation (median, interquartile range). (c) Typical femoral injection site (white arrow) in a 3D
microCT reconstruction at day 21.
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3. Results
3.1. Intrafemoral Injections and Local Engraftment.
Inoculation of MOPC315.BM.Luc cells resulted in 100%
engraftment in ten mice, as demonstrated in vivo by BLI
(Figures 1(a) and 1(b)). Clear signs of established
MOPC315.BM.Luc colonies were observed as early as day
7 (Figure 1(a)). BLI signals increased over the days fol-
lowing injection (Figure 1(b)) and were localized to the
injected right femur (Figure 1(a)). All mice survived the
entire experiment with no signs of suffering and the tu-
mors appeared to steadily grow in the femora for 21 days
during the experiment. All BLI signs were always restricted
to the injected right femur (Figures 1(a) and 1(b)), though
we cannot exclude the possibility that micrometastases
reached other sites (e.g., liver). BLI signals have been
shown to correlate with measurements of serum
MOPC315.BM.Luc secreted immunoglobulin A levels and
were therefore chosen for monitoring tumor growth in the
MOPC315.BM model [6].
3.2. Detection of MOPC315.BM Cells and High Osteoclast
Activity. Following euthanasia, femora were dissected and
analyzed for characteristic signs of MM bone disease. Lon-







Figure 2: TRAP staining of femora injected with PBS (a, b) andMOPC315.BM.Luc cells (c, d) at day 21. (a–d) TRAP staining of the femoral
condyle region to visualize osteoclast activity (purple) at day 21. (b, d) Detailed view of the rectangular area in (a) and (c) showing osteoclast
activity on the surface of trabecular bone (purple, black arrows). Blue indicates nuclei (haematoxylin) counterstain.
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stained with TRAP and revealed high osteoclast activity in
trabecular bone of MM-injected mice (Figures 2(c) and 2(d))
unlike PBS-injected bones (Figures 2(a) and 2(b)).
3.3. Osteolytic Bone Structural Changes Detected by Syn-
chrotron Phase Contrast-Enhanced MicroCT.
Low-resolution microCT scans of MM-injected femora
showed no visible signs of bone structure changes at days 7,
11, 15, and 21 after inoculation (Supplementary Figure 1).
Similarly, reconstructed high-resolution microCTand PCE-
CT images of a PBS-injected bone revealed no signs of
osteolytic bone structure changes at 21 days after inoculation
(Figures 3(a) and 3(b); Figures 4(a) and 4(b)). In contrast, in
a MM-injected femur, high-resolution microCT scans dis-
played characteristic signs of intensive bone resorption at 21
days after inoculation (Figures 3(c) and 3(d); Figures 4(c)
and 4(d)). High bone turnover and cavitation were observed
on the outer bone surfaces, as indicated by multiple trenches





































Figure 3: 3D renderings of high-resolution microCTand PCE-CT for bone ultrastructural characterization of femora injected with PBS (a,
b) versus MOPC315.BM.Luc cells (c, d) at day 21. (a, c) MicroCT images of ventral and dorsal views of one representative femur of PBS-
injected (a) and MM-injected (c) bones. (b, d) Synchrotron PCE-CT 3D reconstructions of the same bones scanned by microCT reveal
higher resolution detail in both ventral and dorsal regions just above the condyles.
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differences were further revealed by region-of-interest im-
aging using PCE-CT (Figure 3(d)). Osteolytic bone struc-
tural changes were seen at the micrometer scale in cross
sections of MM-injected bones (Figures 4(c) and 4(d)). 0e
bone perimeter exhibited an overall jagged appearance with
numerous sites of erosion (Figure 4(c), arrows), mixed with
zones showing low-density newly formed bone (Figure 4(d),
darker greyscale, indicated with #), juxtaposed with mature
bone (Figure 4(d), brighter greyscale). 0e cortical bone was
pocked with irregular-shaped “punched-out” lesions
(Figure 4(d), black arrows). Bone ultrastructural charac-
terization of femora at earlier time points at day 11 (data not
shown) and day 15 (Figure 5) after inoculation showed a
disruption of trabeculae (Figure 5(b)) and signs of bone
healing with low-density newly formed bone in the injected
area (Figure 5(d)), different from what was observed in the
contralateral left femur (Figures 5(a) and 5(c)). PCE-CT
images revealed irregular-shaped osteolytic lesions already
at day 15 (Figures 5(e) and 5(f)).
3.4. Mineralized and Nonmineralized Matrix Changes in the
Osteocyte Lacunar-Canalicular Network. 3D renderings of
lab-CT revealed large cavities in the cortical bone at the
proximal femur of a PBS (Figure 6(a)) and a
MOPC315.BM.Luc cell-injected mouse at day 21 (Figure 6(d)),
corresponding to transcortical blood vessels connecting the
outer surface with the bone marrow (Movie S1 of a MM-in-
jected mouse), as recently demonstrated [19]. Correlative
backscattered electron imaging (BSE; Figures 6(b) and 6(e))
and confocal laser scanning microscopy (CLSM; Figures 6(c)
and 6(f)) allowed direct comparison of mineralized and
nonmineralized matrix changes in the cortical bone. BSE
imaging of MM-injected bones showed irregular small and
larger cavities distributed throughout the cortical bone of the
MM-injected bone, corresponding to intact (indicated with ∗)
and altered (indicated with #) osteocyte lacunae as well as local
changes in the degree of mineralization (Figure 6(e)). PBS-
injected bones revealed only intact (indicated with ∗) osteocyte
lacunae (Figure 6(b)). 0e OLCN was visualized by CLSM
following staining of the bone cavities with rhodamine [16],
which binds to nonmineralized surfaces (Figures 6(c) and 6(f)).
In PBS-injected femora, only well-organized (indicated with ∗)
OLCN was observed (Figure 6(c) and Movie S2 and S3). Large
and irregular-shaped osteocyte lacunae were seen within a
disorganized OLCN architecture in MM-injected bones
(Figure 6(f), indicated with #; Movie S4). In contrast, smaller
flat oval-shaped osteocytes with a well-organized OLCN
arranged in a lamellar structure were visible in the periosteal
region (Figure 6(f), indicated with ∗). CLSM imaging of the
rhodamine-stained sample showed in a second region of in-
terest a similar mixture of disorganized and organized OLCN
next to each other (Supplementary Figure S2).
High-magnification images of the osteocyte morphology
in the MM-injected femur (Figure 6(f)) showed larger, ir-
regular-shaped osteocyte lacunae within a disorganized
canaliculi network architecture (Figure 7(a)) next to flat
osteocyte lacunae organized in a lamellar structure
(Figure 7(b)). Quantification of two regions of interest of the










Figure 4: PCE-CTfor bone ultrastructural characterization of femora injected with PBS (a, b) versusMOPC315.BM.Luc cells (c, d) at day 21.
(a, c) PCE-CT images of cross sections of femur metaphysis. (c) Numerous sites of erosion (black arrows) and bone loss are indicated in the
femur of the MM-injected bone. (b, d) High-magnification view of the rectangular area in (a) and (c). (d) Rectangular area of a local region
in the cortex reveals multiple zones of intensive bone remodeling activity, with low-density new bone (darker grey, indicated with #)
intermixed with mature bone sites (brighter grey), pocked with irregular-shaped “punched-out” lesions (black arrows).
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injected femur revealed that disorganized regions had a greater
lacunae volume (365μm3) and sparser canalicular density
(0.137± 0.11μm/μm3) compared to regions in the PBS-injected
bone (249μm3; 0.155± 0.09μm/μm3; respectively).
Osteocytes communicate with other osteocytes and with
cells on the bone periosteal or endosteal surface, such as
lining cells, stromal cells, osteoblasts, and/or osteoclasts,
through an intricate canaliculi network [20, 21]. 0e con-
nection of the OLCN to the bone marrow on the endosteal
surface revealed a disrupted network in a MM-injected
femur (Figure 7(c)). In a PBS-injected femur, the network
was organized in lamellae parallel to the bone surface and
canaliculi perpendicular to it (Figure 7(d)).
4. Discussion
Our results demonstrate early MM bone disease in adult 26-













Figure 5: MicroCT and PCE-CT images of a control, left (noninjected), and a right femur injected with MOPC315.BM.Luc cells at day 15
after inoculation. Transversal cross sections of high-resolution microCT images of the left (a) and right (b) femur metaphysis demonstrate a
typical region of disrupted trabeculae (highlighted by the rectangular area in (b)). Longitudinal, frontal cross sections of high-resolution
microCT images of the left (c) and right (d) femora showing a region of high bone turnover and bone healing in the rectangular area in (d).
(e) PCE-CTcross-sectional image of the same right femurmetaphysis as shown in (b). (f ) High-magnification view of the rectangular area in
(e) reveals cavitation and irregular-shaped osteolytic lesions in the cortex.
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rationale for using 26-week-old mice was that it has been
documented that these mice reach a state of skeletal maturity
[9, 22, 23]. While housing 26-week-old mice is more ex-
pensive, time-consuming, and tricky as compared to
younger mice, it ascertains the relevance of our model to
study MM bone effects in skeletally mature animals, al-
though we are aware that there is value in studies using
younger aged animals. Our purpose here was to develop a
relevant model resembling as best as is practical adult human
populations, although mice do not have the same osteonal
bones as humans do. Human MM disease develops in aging
populations with a medium age of 69 at first diagnosis. It has
been shown that age-related changes in the BALB/c skeleton
mimic those in aging humans [24]. 0e moment of inertia
increases while the cortical area is maintained during aging
in mice and this is in line with endosteal and periosteal
expansion seen in human long bones [24]. Also, the de-
creased trabecular bone volume fraction observed in aged
mice is comparable to the trabecular bone loss in elderly
humans [24]. Further, the decreased fracture energy de-
tected in aged mice is relevant to the decline in toughness
seen in studies on human cortical bone [24]. In this respect,
younger mice (6 to 16 weeks old) would not resemble the




















Figure 6: Electron and fluorescence confocal laser scanning microscopy for bone ultrastructural characterization of femora injected with PBS
(a–c) andMOPC315.BM.Luc cells (d–f) at day 21. (a, d) 3D renderings of microCTscans of embedded proximal femora showing large cavities
corresponding to blood vessels in the cortical bone. (b, c) Detailed views of the region indicated by the rectangle in (a). (b) BSE image shows
intact osteocyte lacunae (indicated with ∗). (c) CLSM imaging of the rhodamine-stained sample reveals only well-organized OLCN (indicated
with ∗). (e, f) Detailed views of the region indicated by the rectangle in (d). (e) BSE image reveals osteocyte cross sections and local variations in
mineral content, based on signal from the mineralized components of the matrix. (f) CLSM imaging of the rhodamine-stained sample reveals
nonmineralized regions within cortical bone, including osteocyte lacunae and canaliculi network. Correlative BSE and CLSC imaging show flat
osteocyte lacunae organized (indicated with ∗) in a lamellar structure on the periosteal region (Pe) and larger, irregular-shaped lacunae within a
disorganized (indicated with #) canaliculi network architecture in the proximity of the bone marrow (Bm).











Figure 7: High-magnification images of OLCN stained with rhodamine and visualized with fluorescence confocal laser scanning mi-
croscopy. MM-injected femur with (a) larger, irregular-shaped osteocyte lacunae within a disorganized canaliculi network architecture in
proximity to the bone marrow (indicated with # in Figure 3(f)) and (b) flat osteocyte lacunae organized in a lamellar structure on the
periosteal side (indicated with ∗ in Figure 3(f )). High-magnification image of the connection of the osteocyte canaliculi network to the bone
marrow on the endosteal surface of (c) a MM-injected femur with a disrupted network and (d) a healthy control mouse femur illustrating an
organized network in lamellae parallel to the bone surface and canaliculi perpendicular to them.
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makes it feasible both to study all stages of rapid MM bone
disease and to test new treatment protocols in the future.
Our newly developed syngeneic model is locally confined
and shows potential for future characterization of different
stages of the disease down to the ultrastructural level. It
differs substantially from previously established syngeneic
models such as the 5TMM model, where two distinctly
different MM cell lines are used: (i) the moderate 5T2MM
cells or (ii) the more aggressive 5T33MM cells. In both cases,
MM cells must be injected intravenously (i.v.) into young 6-
week-old mice with osteolytic lesions appearing only after
11∼16 weeks, when mice showed end-stage disease and
tumors [25, 26]. While useful for some studies, lesions in
these models are not primarily localized to one particular
bone [26], as is the case in our model. In the aggressive
5T33MMmodel as in theMOPC315.BM.Luc model after i.v.
injection [6], tumors grow in multiple organs including
nonhematopoietic tissue. Mice often succumb to the disease
without necessarily showing signs of lesions in long bones.
All these make it difficult to track specific stages of MM bone
disease development, a challenge that our MOPC315.BM.-
Luc model circumvents.
Our newly established model in skeletally mature bones
of BALB/c mice provides a unique tool for studying MM
bone disease in different stages of disease progression, for at
least 3 weeks after MM cell injection. 0e results shown here
provide first insights into quantitative data of the BLI of mice
3, 7, 11, 15, and 21 days after i.f. MOPC315.BM.Luc cell
inoculation, and qualitative data based on high-resolution
microCT and PCE-CT and confocal and electron micros-
copy, as proof of concept for the detection of subtle ultra-
structural changes in the extracellular matrix of MM-
affected bones.0emodel is strengthened by its confinement
to one particular bone, thus minimizing animal suffering
and improving localization, which is essential for using high-
resolution characterization methods in restricted small
regions.
Detection of increased osteoclast activity evidenced by
TRAP staining indicates active osteolytic disease in
MOPC315.BM.Luc-injected mice. In future studies, our
model can be used for the detection of osteoblast sup-
pression, which is a hallmark of myeloma bone disease.
Expression of markers for osteogenic differentiation such as
the osteocytic marker sclerostin, dentin matrix protein 1,
and fibroblast growth factor 23, as well as the osteogenic
markers alkaline phosphatase, bone c-carboxylglutamic
acid-containing protein, and osteopontin, could be com-
pared between PBS- andMOPC315.BM.Luc-injected femora
by immunohistochemical analysis.
Contemporary research of bone tissue routinely employs
microCTwith resolutions down to 5∼10 micrometers. High-
resolution microCT down to and below one micrometer is
challenging but is important to identify and characterize the
length scale of osteocytes. Although increasingly studied by
high-resolution microCT, synchrotron-based PCE-CTscans
reveal structural attributes with target resolutions below
100 nm, in realistic millimeter-sized samples. 0us, com-
bining high-resolution microCTwith synchrotron PCE-CT,
it is possible to detect osteolytic bone structural changes in
the sub-micrometer scale. With PCE-CT, all bone com-
partments may be visualized in 3D, including subtle dif-
ferences in the degree of mineralization of the bones [27]. In
this manner, important density differences and gradients are
revealed by synchrotron beamlines employing advanced
iterative methods of ptychography, and they are well able to
spatially map small changes below <100 nm resolution,
within millimeter-sized samples of tooth dentin [28]. Future
studies of MM-affected bones will thus provide insights into
the very early stages of MM bone disease.
We detected increased osteoclastic activity on the bone
interface. Furthermore, complementary analyses using BSE
and CLSM allowed the detection of changes in the bone
ultrastructure, down to single osteocyte lacunae and
canaliculi network in the nanometer scale revealing spatial
alterations in the network architecture. Large and irregular-
shaped osteocyte lacunae detected within the disorganized
OLCN suggest locally altered bone remodeling, probably
indicating increased bone destruction in the perilacunar
space in MM-injected femora. In addition to the altered size
and shape of osteocyte lacunae, the disrupted canaliculi
network architecture is indicative of a bone pathology in our
MM bone disease model. Indeed, it is well known that
changes in the bone ultrastructure result in pathological
conditions, such as osteoporosis. A recent study on a murine
osteoporosis model investigates the influence of lacunar-
canalicular permeability and vascular porosity on the fluid
flow magnitude and shows that this was significantly re-
duced in an osteoporotic condition as modeled with
ovariectomized rats [29]. 0is reduction in fluid flow could
impair the mechanosensory function of osteocytes and lead
to age-related bone loss in postmenopausal osteoporosis
[29].
Our model thus paves the way for combining comple-
mentary modalities for characterizing the extracellular
matrix ultrastructure, with great potential for a deeper
understanding of the pathological changes at all stages of
MM disease. Such information is critical for the develop-
ment of next-generation treatment approaches.
In summary, we developed an in vivo, confined MM
disease model, in skeletally mature (26 weeks old) BALB/c
mice affecting femora of mice. 0is model will allow future
combined biomaterial science and pharmacological inves-
tigations for early detection and treatment of MM.
Data Availability
0e data used to support the findings of this study are in-
cluded within the article.
Conflicts of Interest
0e authors declare no conflicts of interest.
Authors’ Contributions
FJ, PZ, and AC were responsible for the study design and
drafted the manuscript. FZ, AP, IMJ, AC, PZ, and FJ col-
lected the data. FZ, AR, IMJ, AC, PZ, and FJ performed data
10 Journal of Oncology
analysis. FZ, IMJ, AC, PZ, and FJ interpreted the data. BB
was responsible for the contribution of cell line. All authors
approved the final version of the manuscript.
Acknowledgments
0e authors thank Georg Duda (Julius Wolff Institute,
Charite´ Universita¨tsmedizin Berlin, Germany) for access to
the microCT. 0e authors also thank Daniela S Garske
and Jeannette Steffen for excellent technical support and
Alexander Van Tol for help with quantitative analysis of
OLCN. 0is work was financially supported by a grant from
the German Research Foundation to FJ (JU 426/5-1). 0e
authors acknowledge the European Synchrotron Radiation
Facility (ESRF) for beamtime on ID19. AC is supported by
an Emmy Noether Grant of the German Research Foun-
dation (CI 203/2-1). IMJ is financed by a Humboldt Re-
search Fellowship for postdoctoral researchers.
Supplementary Materials
Supplementary Figure S1: Low-resolution lab-CT images of
ventral and dorsal views of a representative femur of MM-
injected bones at day (A) 7, (B) 11, (C) 15, and (D) 21,
respectively. Supplementary Figure 2: Electron and confocal
microscopy for bone ultrastructural characterization of
femora injected with MOPC315.BM.Luc cells at day 21. (A)
3D rendering of a microCT scan, (B) BSE image of the
proximal femur, and (C) CLSM imaging of the rhodamine-
stained sample showing a detailed view of the region in-
dicated by the rectangle in B. Bv indicates a transcortical
blood vessel, Bm indicates bone marrow, and Pe indicates
periosteal side. Movie S1: High-resolution lab-CT (voxel size
2.5 μm) movie of a PMMA-embedded proximal femur 21
days after injection of MM cells. Movie shows that the large
cavities in the cortical bone are channels that connect the
outer surface with the bone marrow. Movie corresponds to
Figure 6(d). Movie S2: OLCN of a PBS-injected femur
stained with rhodamine and visualized with fluorescence
confocal laser scanning microscopy. Still image corresponds
to Figure 6(c). Magnification 40x, oil objective, 0.75 zoom, 6
tiles, 60 μm total depth at 0.4 μm step size. Movie S3: OLCN
of a PBS-injected femur stained with rhodamine and vi-
sualized with fluorescence confocal laser scanning micros-
copy. Detail view of a region below the region indicated by
the rectangle in Figure 6(a). Magnification 40x, oil objective,
0.75 zoom, 6 tiles, 60 μm total depth at 0.4 μm step size.
Movie S4: OLCN of a MM-injected femur stained with
rhodamine and visualized with fluorescence confocal laser
scanning microscopy. Still image corresponds to Figure 6(f).
Magnification 40x, oil objective, 0.75 zoom, 6 tiles, 60 μm
total depth at 0.4 μm step size. (Supplementary Materials)
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